Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
PBE Quote, Financials, Valuation and Earnings
Last price:
$82.00
Seasonality move
:
-1.34%
Day range:
$80.93 - $82.13
52-week range:
$54.52 - $85.73
Dividend yield:
1%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.5K
Avg. volume:
6.7K
1-year change:
24.63%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$81.98 | -- | -- | -- | $0.42 | 1% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$208.69 | -- | -- | -- | $1.17 | 0% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$108.37 | -- | -- | -- | $0.25 | 0.94% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$33.26 | -- | -- | -- | $0.05 | 0.67% | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
$88.40 | -- | -- | -- | $0.02 | 0.08% | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
$57.34 | -- | -- | -- | $0.11 | 0.81% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.622 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.393 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -0.012 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 0.353 | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | 0.802 | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | 0.169 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
State Street SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
State Street SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About PBE or FBT?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe Invesco Biotechnology & Genome ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is PBE or FBT More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.137% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.734, suggesting its less volatile than the S&P 500 by 26.595%.
-
Which is a Better Dividend Stock PBE or FBT?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 1%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0% to investors and pays a quarterly dividend of $1.17 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or FBT?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.137% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.1%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 1%. Invesco Pharmaceuticals ETF offers a yield of 0.94% to investors and pays a quarterly dividend of $0.25 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About PBE or RSPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is PBE or RSPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.137% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.362%.
-
Which is a Better Dividend Stock PBE or RSPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 1%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.67% to investors and pays a quarterly dividend of $0.05 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or RSPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
-
Which has Higher Returns PBE or XHE?
State Street SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About PBE or XHE?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Health Care Equipment ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XHEState Street SPDR S&P Health Care Equipment ETF0 0 0 -
Is PBE or XHE More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.137% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Equipment ETF has a beta of 1.123, suggesting its more volatile than the S&P 500 by 12.312%.
-
Which is a Better Dividend Stock PBE or XHE?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 1%. State Street SPDR S&P Health Care Equipment ETF offers a yield of 0.08% to investors and pays a quarterly dividend of $0.02 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XHE?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Equipment ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Health Care Equipment ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XHEState Street SPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
State Street SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat State Street SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than State Street SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than State Street SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHState Street SPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.137% less volatile than S&P 500. In comparison State Street SPDR S&P Pharmaceuticals ETF has a beta of 0.636, suggesting its less volatile than the S&P 500 by 36.438%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.42 per share corresponding to a yield of 1%. State Street SPDR S&P Pharmaceuticals ETF offers a yield of 0.81% to investors and pays a quarterly dividend of $0.11 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. State Street SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than State Street SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while State Street SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for State Street SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHState Street SPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
